Biocon ties up with Bayer HealthCare to market its insulin in China

摘要

Biocon Ltd has signed a licensing agreement with Bayer HealthCare(BHC)for exclusive marketing and trademark rights for 'Insugen',a recombinant human insulin,for the Chinese market.After completion of necessary local registration trials,'Insugen' is expected to be launched within the next two to three years in China."It is envisaged,that the collaboration will be expanded to other countries in Asia-Pacific",Biocon said in a press statement.